Trials / Terminated
TerminatedNCT00479622
Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus
A Randomized, Two-Arm, Parallel Group Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Added to Standard Therapy in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine how the body absorbs and chemically changes a single infusion of TRU-015 in subjects with kidney disease caused by lupus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRU-015 | Arm 1 = 800 mg Arm 2 = 2000 mg |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2007-05-28
- Last updated
- 2008-05-08
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00479622. Inclusion in this directory is not an endorsement.